We are live on ! Find out more
CM

Castleark Management Portfolio holdings

AUM $3.71B
1-Year Est. Return 65.19%
This Fund
S&P 500
This Quarter Est. Return
+14.75%
1 Year Est. Return
+65.19%
3 Year Est. Return
+247.97%
5 Year Est. Return
+412.62%
10 Year Est. Return
+3,903.2%
AUM
$3.48B
AUM Growth
+$231M
Cap. Flow
-$87.3M
Cap. Flow %
-2.51%
Top 10 Hldgs %
17.4%
Holding
433
New
64
Increased
81
Reduced
104
Closed
64

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$29M
2
CNC icon
Centene
CNC
+$17.6M
3
KBR icon
KBR
KBR
+$16.5M
4
CDW icon
CDW
CDW
+$16.2M
5
IQV icon
IQVIA
IQV
+$16.1M

Top Sells

Rank Stock Value
1
SCHW
Charles Schwab
SCHW
+$27M
2
PVH icon
PVH
PVH
+$18.7M
3
TPR icon
Tapestry
TPR
+$18.2M
4
IART icon
Integra LifeSciences
IART
+$18.1M
5
MTZ icon
MasTec
MTZ
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 24.56%
2 Technology 18%
3 Consumer Discretionary 12.44%
4 Industrials 12.24%
5 Energy 10.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDNA icon
176
CareDx
CDNA
$2.74B
$6.01M 0.17%
+208,235
New +$3.9M
VCEL icon
177
Vericel Corp
VCEL
$2.07B
$5.99M 0.17%
423,597
-296,988
-41% -$3.48M
CVX icon
178
Chevron
CVX
$419B
$5.95M 0.17%
48,695
– –
QGEN icon
179
Qiagen
QGEN
$8.84B
$5.94M 0.17%
147,862
-12,462
-8% -$498K
BP icon
180
BP
BP
$119B
$5.9M 0.17%
134,083
-66,840
-33% -$2.79M
PPLI
181
People Inc
PPLI
$2.83B
$5.87M 0.17%
151,636
-65,690
-30% -$2.13M
FLS icon
182
Flowserve
FLS
$9.25B
$5.81M 0.17%
+106,275
New +$5.15M
LOPE icon
183
Grand Canyon Education
LOPE
$3.99B
$5.77M 0.17%
+51,180
New +$5.97M
NBIX icon
184
Neurocrine Biosciences
NBIX
$15.3B
$5.74M 0.16%
46,665
+4,195
+10% +$476K
WRD
185
DELISTED
WildHorse Resource Development
WRD
$5.68M 0.16%
+240,135
New +$5.16M
VNOM icon
186
Viper Energy
VNOM
$8.44B
$5.62M 0.16%
133,453
– –
LOXO
187
DELISTED
Loxo Oncology, Inc
LOXO
$5.54M 0.16%
32,445
-1,150
-3% -$193K
CW icon
188
Curtiss-Wright
CW
$20.9B
$5.44M 0.16%
+39,600
New +$5.19M
WST icon
189
West Pharmaceutical
WST
$25.5B
$5.4M 0.16%
+43,755
New +$4.91M
BIO icon
190
Bio-Rad Laboratories Class A
BIO
$10.1B
$5.32M 0.15%
16,980
-1,510
-8% -$469K
NNN icon
191
NNN REIT
NNN
$8.3B
$5.31M 0.15%
+118,560
New +$5.34M
SRDX
192
DELISTED
Surmodics
SRDX
$5.3M 0.15%
+70,960
New +$4.89M
PSXP
193
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
$5.2M 0.15%
101,669
– –
VRTX icon
194
Vertex Pharmaceuticals
VRTX
$130B
$5.17M 0.15%
26,830
– –
SU icon
195
Suncor Energy
SU
$82.3B
$5.09M 0.15%
131,490
– –
RDS.A
196
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$4.99M 0.14%
73,200
– –
ESV
197
DELISTED
Ensco Rowan plc
ESV
$4.91M 0.14%
145,408
– –
TCMD icon
198
Tactile Systems Technology
TCMD
$515M
$4.88M 0.14%
+68,750
New +$4.13M
AMD icon
199
Advanced Micro Devices
AMD
$858B
$4.7M 0.14%
+152,250
New +$3.44M
EQNR icon
200
Equinor
EQNR
$107B
$4.63M 0.13%
164,260
– –
6 7
8
9 10

Similar funds

MSC
MUFG Securities (Canada) New York $3.71B AUM 38.19% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
HCM
Himalaya Capital Management Seattle, Washington $3.7B AUM 39.18% 1-Year Est. Return
OH
Osiris Holdings Monaco $3.72B AUM
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.7B AUM 32.64% 1-Year Est. Return
MCM
MKP Capital Management New York $3.7B AUM 23.18% 1-Year Est. Return

Castleark Management's Q3 2018 Portfolio in Review

As of Q3 2018, Castleark Management held 433 positions worth $3.48B, up 7.1% from $3.25B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Castleark Management's Q3 2018 filing shows 64 new, 81 increased, 104 reduced and 64 closed positions. Its largest new stake was Eli Lilly: 289,654 shares worth $31.1M. The largest sale was Charles Schwab, an estimated $27M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Castleark Management's largest Q3 2018 buy was Eli Lilly: 289,654 shares worth $31.1M.
  • Castleark Management added most to CDW in Q3 2018, an estimated $16.2M increase.
  • Castleark Management's biggest Q3 2018 reduction was Charles Schwab, cutting an estimated $27M.
  • Castleark Management fully exited Tapestry in Q3 2018, selling an estimated $18.2M.
  • Castleark Management's ten largest holdings make up 17% of its $3.48B portfolio in Q3 2018.
  • Castleark Management opened 64 new positions and closed 64 in Q3 2018.
  • Castleark Management's portfolio value rose 7.1% quarter-over-quarter to $3.48B.

Based on Castleark Management's 13F filing for Q3 2018, filed 15 Nov 2018.